Ensayos clínicos

8.676 ensayos encontrados

ReclutandoClinicalTrials.gov

Argentinean Registry on the Management of Helicobacter Pylori Infection

OBSERVATIONALInicio: 17 de may de 2021ID: NCT06579365

ReclutandoFase 2ClinicalTrials.gov

An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Asthma Who Participated in Study DRI16762 or ACT18301

INTERVENTIONALInicio: 30 de sept de 2024ID: NCT06609239

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, 24-week, Randomized, Double-blind, Parallel-group Bayesian Dynamic Borrowing Study Comparing the Efficacy, Safety, Tolerability and Pharmacokinetics of FF/UMEC/VI With FF/VI in 12-17-year-old Participants With Inadequately Controlled Asthma on Stable Maintenance Therapy With ICS/LABA

INTERVENTIONALInicio: 25 de abr de 2023ID: NCT05757102

ReclutandoFase 3ClinicalTrials.gov

Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

INTERVENTIONALInicio: 16 de ene de 2026ID: NCT07195695

ReclutandoClinicalTrials.gov

PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

OBSERVATIONALInicio: 3 de abr de 2020ID: NCT04142437

ReclutandoFase 3ClinicalTrials.gov

A Phase 2b/3, Randomized, Double-blind, Placebocontrolled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

INTERVENTIONALInicio: 16 de sept de 2025ID: NCT07190209

ReclutandoFase 2ClinicalTrials.gov

A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

INTERVENTIONALInicio: 7 de nov de 2024ID: NCT06676319

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

INTERVENTIONALInicio: 9 de abr de 2025ID: NCT06824467

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

INTERVENTIONALInicio: 13 de mar de 2024ID: NCT06318169

ReclutandoClinicalTrials.gov

Body Composition Estimated by Bioelectrical Impedance Analysis in Patients with Acute Coronary Syndrome.

OBSERVATIONALInicio: 11 de feb de 2023ID: NCT06561815

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

INTERVENTIONALInicio: 31 de mar de 2026ID: NCT05199688

ReclutandoFase 3ClinicalTrials.gov

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

INTERVENTIONALInicio: 2 de dic de 2020ID: NCT04613596

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

INTERVENTIONALInicio: 13 de ago de 2024ID: NCT06508658

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

INTERVENTIONALInicio: 27 de nov de 2024ID: NCT06627647

ReclutandoFase 3ClinicalTrials.gov

Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

INTERVENTIONALInicio: 17 de jul de 2024ID: NCT06252649

ReclutandoClinicalTrials.gov

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure (ACLF): iNdications and outComEs

OBSERVATIONALInicio: 8 de jul de 2021ID: NCT04613921

ReclutandoFase 3ClinicalTrials.gov

18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

INTERVENTIONALInicio: 30 de jun de 2025ID: NCT07054515

ReclutandoClinicalTrials.gov

A Long-Term, Prospective, Observational, Registry of Patients With Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated With Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)

OBSERVATIONALInicio: 1 de feb de 2024ID: NCT05966467

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

INTERVENTIONALInicio: 17 de jul de 2025ID: NCT06765109

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial

INTERVENTIONALInicio: 24 de oct de 2023ID: NCT05949684